Mitochondrial dysfunction during in vitro hepatocyte steatosis is reversed by omega-3 fatty acid-induced up-regulation of mitofusin 2

Metabolism: Clinical and Experimental

Volumn 60, Issue 6, 2011, Pages 767-775

  Zhang, Yong ^a   Jiang, Longchang ^a   Hu, Wenjun ^a   Zheng, Qichang ^a   Xiang, Wenpei ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DOCOSAHEXAENOIC ACID; FAT DROPLET; ICOSAPENTAENOIC ACID; MESSENGER RNA; MITOFUSIN 2; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FATTY LIVER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CELL; LIVER MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; AZO COMPOUNDS; BLOTTING, WESTERN; CELLS, CULTURED; COLORING AGENTS; FATTY ACIDS, OMEGA-3; FATTY LIVER; FLUOROMETRY; HEPATOCYTES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA, LIVER; MITOCHONDRIAL PROTEINS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 79956099507     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.07.026     Document Type: Article

References (50)

1. Bedogni G, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52. (Pubitemid 40911310)
2. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009;8(Suppl 1) S4-S8.
3. Adams LA, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21. (Pubitemid 41002048)
4. Chen DF. [Epidemiology and the natural history of nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing Za Zhi 2008;16:804-5.
5. Fetterman JJ, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease.AmJ Health Syst Pharm 2009;66:1169-79.
6. Shirouchi B, et al. Effect of dietary omega 3 phosphatidylcholine on obesity-related disorders in obese Otsuka Long-Evans Tokushima fatty rats. J Agric Food Chem 2007;55:7170-6. (Pubitemid 47338962)
7. Oliveira CP, et al. Liver mitochondrial dysfunction and oxidative stress in the pathogenesis of experimental nonalcoholic fatty liver disease. Braz J Med Biol Res 2006;39:189-94.
8. Mantena SK, et al. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 2008;44:1259-72.
9. Pessayre D, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57-69. (Pubitemid 32240486)
10. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 1997;26(Suppl 1):13-22. (Pubitemid 127777233)
11. Chen H, Chan DC. Emerging functions of mammalian mitochondrial fusion and fission. Hum Mol Genet 2005;14(Spec No 2):R283-9.
12. Chen H, Chan DC. Mitochondrial dynamics - fusion, fission, movement, and mitophagy - in neurodegenerative diseases. Hum Mol Genet 2009;18(R2):R169-76.
13. Chan DC. Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol 2006;22:79-99.
14. Nunnari J, et al. Mitochondrial transmission during mating in Saccharomyces cerevisiae is determined by mitochondrial fusion and fission and the intramitochondrial segregation of mitochondrial DNA. Mol Biol Cell 1997;8:1233-42. (Pubitemid 27310471)
15. Suelmann R, Fischer R. Mitochondrial movement and morphology depend on an intact actin cytoskeleton in Aspergillus nidulans. Cell Motil Cytoskeleton 2000;45:42-50.
16. Collins TJ, et al. Mitochondria are morphologically and functionally heterogeneous within cells. EMBO J 2002;21:1616-27. (Pubitemid 34614618)
17. Benard G, et al. Mitochondrial bioenergetics and structural network organization. J Cell Sci 2007;120(Pt 5):838-48.
18. Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 2005;280:26185-92. (Pubitemid 41022214)
19. Jensen RE, et al. Yeast mitochondrial dynamics: fusion, division, segregation, and shape. Microsc Res Tech 2000;51:573-83. (Pubitemid 32046166)
20. Shaw JM, Nunnari J. Mitochondrial dynamics and division in budding yeast. Trends Cell Biol 2002;12:178-84. (Pubitemid 34442240)
21. Chung KW, et al. Early onset severe and late-onset mild Charcot- Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain 2006;129(Pt 8):2103-18. (Pubitemid 44289075)
22. Bach D, et al. Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6. Diabetes 2005;54:2685-93. (Pubitemid 41233591)
23. Verhoeven K, et al. MFN2 mutation distribution and genotype/ phenotype correlation in Charcot-Marie-Tooth type 2. Brain 2006;129 (Pt 8):2093-102. (Pubitemid 44289074)
24. Bach D, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem 2003;278:17190-7. (Pubitemid 36799599)
25. Gomez-Lechon MJ, et al. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 2007;165:106-16. (Pubitemid 46072796)
26. Mori M, et al. Foam cell formation containing lipid droplets enriched with free cholesterol by hyperlipidemic serum. J Lipid Res 2001;42:1771-81. (Pubitemid 33116708)
27. Greenspan P, Fowler SD. Spectrofluorometric studies of the lipid probe, nile red. J Lipid Res 1985;26:781-9. (Pubitemid 15046441)
28. McMillian MK, et al. Nile red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitr Mol Toxicol 2001;14:177-90. (Pubitemid 34326670)
29. Donato MT, et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 2006;34:1556-62. (Pubitemid 44285398)
30. Gomez-Lechon MJ, et al. Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS. Biochem Pharmacol 2003;66:2155-67. (Pubitemid 37383730)
31. Zhao G, et al. Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 cells. Biochem Biophys Res Commun 2005;336:909-17. (Pubitemid 41338355)
32. Ouhabi R, Boue-Grabot M, Mazat JP. Mitochondrial ATP synthesis in permeabilized cells: assessment of the ATP/O values in situ. Anal Biochem 1998;263:169-75. (Pubitemid 28480801)
33. Gonzalez-Periz A, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009;23:1946-57.
34. Spady DK. Regulatory effects of individual n-6 and n-3 polyunsaturated fatty acids on LDL transport in the rat. J Lipid Res 1993;34:1337-46. (Pubitemid 23230311)
35. Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2009.
36. Xin YN, et al. Omega-3 polyunsaturated fatty acids: a specific liver drug for non-alcoholic fatty liver disease (NAFLD). Med Hypotheses 2008;71:820-1.
37. Johannsen DL, Ravussin E. The role of mitochondria in health and disease. Curr Opin Pharmacol 2009;9:780-6.
38. Schiff M, et al. Mitochondria and diabetes mellitus: untangling a conflictive relationship? J Inherit Metab Dis 2009;32:684-98.
39. Wilms L, et al. Evidence of mitochondrial dysfunction in obese adolescents. Acta Paediatr 2009.
40. Wei Y, et al. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008;14:193-9. (Pubitemid 351314298)
41. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-5.
42. Rohrbach S. Effects of dietary polyunsaturated fatty acids on mitochondria. Curr Pharm Des 2009;15:4103-16.
43. Hensley K, et al. Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis 2000;21:983-9.
44. Perez-Carreras M, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38:999-1007. (Pubitemid 37221683)
45. Tsai CH, Li TC, Lin CC. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J 2008;101:900-5.
46. Cortez-Pinto H, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659-64. (Pubitemid 29513973)
47. Yu T, et al. Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. Cardiovasc Res 2008;79:341-51. (Pubitemid 351951612)
48. Zorzano A, et al. Role of novel mitochondrial proteins in energy balance. Rev Med Univ Navarra 2004;48:30-5.
49. Navarro A, Boveris A. The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol 2007;292: C670-C686.
50. Terada H. Uncouplers of oxidative phosphorylation. Environ Health Perspect 1990;87:213-8. (Pubitemid 20316919)